The Aequitas Group
Health Economics Analysis - Crohn's Disease
A specialty pharmaceutical company, in its efforts to secure and sustain appropriate reimbursement for its product for mild to moderate Crohn’s disease, commissioned The Aequitas Group to undertake a cost-effectiveness analysis to support product positioning with commercial and government payors.
The Aequitas Group completed a health economics analysis (HEA) to support the reimbursement strategy for the product. The results helped determine the incremental cost-effectiveness of the client’s product compared to existing products already in the marketplace for the same indication, while revealing the price at which the client’s product would be the most cost-effective option.
By completing a formal HEA, derived from on evidence-based methods used by commercial and government payors in the U.S., The Aequitas Group was able to provide the client with value messages to inform their comprehensive product positioning strategies.
© 2009 The Aequitas Group, Inc. All Rights Reserved.